To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
Long time biotech and tech investor who enjoys discussing stocks, options, and sharing ideas freely.
Investors buy or sell at their own risk. All my articles strictly represent an 'opinion' and in no-way should be construed as individual investor advice.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Forty year career in finance and executive management beginning on Coopers & Lybrand audit staff (CPA) culminating with twenty-six years as CEO of publicly-held companies. Prior to that and after leaving C&L served in CFO and COO capacities, all in publicly-held companies. Was an EDGAR Pilot Program filer in 1984, one of eighteen if my memory is correct.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Former Investment Representative with large private firm. BBA degree in Marketing. Have been investing in stocks for 30 years. Consider myself an investor, not a trader. Believe day trading is a losers game and that most who partake are wasting their lives and will end up broke. Most holdings held for months or years.
I am a retired global analyst, currently busy in investing and writing articles about stocks at several investing publications and websites. I have also developed strategies for creating winning portfolios according to specific formulas.
In January 2015, I was ranked among the world’s top 10 financial bloggers according to TipRanks, which holds financial experts accountable for their recommendations by disclosing their stock ratings since 2009:
A regular guy (still alive from New York!) who shows how he would manage a model (not actual) portfolio for educational purposes only, my personal finances are my own business and the disclosure statement is only for the portfolio we are discussing. I give absolutely no advise, and only offer suggestions on how I could manage a portfolio.
The main reason for a subscriber to "Follow" me, especially for the model portfolios (TARP or otherwise), is to glean some knowledge to become a better investor and not simply place bets. Money management is every bit as important as any other aspect of investing, and by following a portfolio and the actions taken, you can gain some insight into a somewhat higher level of investing acumen. There are no requirements, and this is not "rocket science" - it is simply a powerful way for you to put the money you have worked hard for to work even harder for you. My message will be consistent, and my hope by doing this is to share my own experiences, illustrated in the model mock portfolios I build exclusively for Seeking Alpha. Knowledge is power, and many folks shy away from the investing world because that very world makes it more confusing each and every day in an effort to sell you something: stock picks, technical strategies, books, videos, subscriptions with "secret ideas," gadgets, and even snake oil. My promise to you is that my work here will remain free to all of my followers, with the hope of giving to you some of the things that took years for me to learn myself.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
David is currently on hiatus from blogging as he is now working for a middle market investment banking in Dx Equity Research. His prior experience included medtech banking at AmeriTech Advisors. He was formerly an associate at a Silicon Valley venture fund called AVP Ventures. Prior to venture, David worked at Life Science holding company known as Genextra where he was an analyst covering the molecular diagnostics space. David has worked as an associate and analyst in consulting for personalized medicine companies and worked in life science equity research at ThinkEquity Partners. David is a CFA charterholder. David received his BA in Business Administration from SFSU and a Masters in Finance from Università Bocconi in Milan, Italy where he wrote a thesis titled: “Life Science Valuation Complications and Solutions with Applications to Molecular Diagnostics.” Hobbies include: Wine tasting, weight lifting, traveling, and playing guitar.
TheStreetSweeper recently named Sonya Colberg as Senior Editor. About five years ago, she became senior investigative reporter of TheStreetSweeper, a website devoted to exposing fraud, shenanigans and lousy business practices of public companies. Sonya had worked more than two decades as an editor and reporter for two major newspapers, including the recent Warren Buffett acquisition, Tulsa World. Among others, the Associated Press, Great Plains Journalism Awards, The Gerald Loeb Awards and the Society of Professional Journalists have recognized Sonya’s investigative, feature, health, news and business stories. A fearless investigative reporter, Sonya loves nothing better than calling out the shysters and bumblers who quietly work to separate investors from their hard-earned money.
Contact TheStreetSweeper at firstname.lastname@example.org
I'm a well-informed retail investor and post on SA in order to expose my thought process to critical examination and comment from readers. It makes me a better investor. I'm particularly proud of bullish macro articles posted in 2009 and later, in which I presented ideas that encouraged me to invest very profitably in a rising market. I also did articles on individual stocks, many of which contained insights not available elsewhere. Finally, I wrote a number of thoughtful articles critical of financialism and the lack of ethics on Wall Street. I do not post for compensation, as I am concerned that editorial policy encourages and pays a premium for articles that invite the reader to speculate on the short term movements of microcaps, penny stocks, and controversial issues. The best way for me to monetize my insights is to invest accordingly. As a retail investor, I don't give investment advice. I write about what I'm investing in, and the thought process involved in decision making and stock selection. Hopefully some of what I write is of benefit to others, by sharing my experience as I interpret it and helping them improve their investment thinking and process.
I have been a technology investor for over twenty-five years. My investing style includes a combination of Fundamental Analysis with Technical Analysis used for entry and exit points. I have followed several stocks involved in patent litigations including Rambus (RMBS), Interdigital (IDCC), Tessera (TSRA) and Star Scientific (STSI). I follow the actual trials, read the transcripts and the briefs and attempt to handicap the outcomes. I attend various hearings, trials, and oral arguments whenever possible, including appeals to the CAFC, and occasionally attend hearings/trials at various District Courts and the ITC. I have attended over 30 oral arguments at the CAFC and I have a good feel for the various judges.
Star Scientific (STSI) is my favorite stock for 2014. STSI has transformed themselves from a tobacco company to a Biopharma company in 2012 and 2013, and this year we will see the true value of the company now that scientific researchers are running the company. Star Scientific will also probably be changing their name in 2014, and may choose to become known as Rock Creek Pharmaceuticals (their division that produces Anatabloc). Although STSI has exited the tobacco manufacturing business (and settled with RJR for a paltry $5 Million), they still own key tobacco curing patents that have been validated by both the USPTO and the CAFC, and these patents don't expire until 2018. Star's new TSNA BDL patent (granted in 2012 by the USPTO) doesn't expire until 2030. I expect STSI (Rock Creek) to have a banner year in 2014 as the world starts to learn the miraculous ability of Anatabloc to treat a variety of auto immune diseases and other conditions associated with NF-kB inflammation (including MS, Rheumatoid Arthritis, Asthma, Crohn's, Parkinson's, Traumatic Brain Injury, Alzheimer's, and various types of cancer, etc). Rock Creek Pharmaceuticals should have more and more peer reviewed medical journal articles on the efficacy of Anatabloc coming out in 2014. I also expect that Rock Creek will file several drug applications (IND's) with the FDA in 2014. In addition, I expect Rock Creek Pharmaceuticals to team or partner with one or more Big Pharma companies for various human ailments as they pursue these IND's. For all these reasons, I expect Star Scientific to be at least a $10 stock before the end of the 2014, and possibly much higher than that.
CEO of StockDotGenie.Com, a Technical Analysis (TA) charting platform targeted at new and novice traders who want to incorporate TA into their trading skills, but without taking years to learn and master the finer points.
YouTube Video on StockDotGenie: https://www.youtube.com/watch?v=kK1_x3Czuso
The educational website that supports the trading site is a practical and fundamental base for new traders to obtain an appreciation of both TA and the importance of correctly managing risk. My major at Missouri Western State Univ. was Computer Science. Beginning in 1989 I was the research director of a non-profit clinical research foundation then called Search Alliance. Our research focus included vaccines and antivirals. I subsequently started BioLogic, a consulting firm that focused on partnering emerging biotech’s with large Pharmaceuticals. BioLogic was instrumental in obtaining large pharmaceutical deals for the biotech's we represented. I invest in stocks utilizing every shred of information that technical, fundamental, human, social and internet sciences can provide. The more you know about a companies products, services, customers and investors, the greater your chances of being on the right side of a trade. "There are lots of shortcuts to losing money." Email: email@example.com
John Eastman is a writer, mixed media artist, and founder of several businesses (www.redfishcreative.com) (www.eastmantribe.com)with over 25 years of hands-on business and entrepreneurial experience. He currently works and resides in a studio loft in Pittsburgh, Pennsylvania and NYC. Mr. Eastman has exhibited and read in various galleries and exhibits in the region as an artist and writer.
Mr. Eastman is the co-founder of www.smallcapcity.com, an online publication that focuses on small capitalized public firms, founder of www.blackandwhiteprogram.com, an online publication offering interviews, essays, and reports. He also writes for www.thechairmansblog.com, www.smallcapcity.com, Motley Fool, and several other online and print publications.
Mr. Eastman’s business background commenced in 1985 with the launch of a series of high tech, real estate, and design firms. He has extensive experience in banking and loan servicing, real estate property management and asset management, asset appraisal and valuation, Office of Thrift Supervision (OTS) and FDIC bank closure proceedings.
As director of research at Portfolio123, I have long specialized in rules/factor-based equity investing strategies of the sort characterized as “Smart Alpha” in the July 2014 Journal of Portfolio Management. In addition, I formerly managed a high-yield fixed-income fund and conducted research involving quantitative asset allocation strategies such as are at the foundation of what today has come to be known as Robo Advising. I formerly edited the the Forbes Low Priced Stock Report, and served as an assistant research director at Value Line. I have long had a passion for investor education, which has resulted in my having conducted numerous seminars on stock selection and analysis, and the authoring of two books: Screening The Market and The Value Connection.
Mark Mansfield has 3 years of experience in brokerage with Fidelity Investments. Mark has passed two levels of the Chartered Financial Analyst exam, interned as a fixed income analyst for Principal Global Investors, and has an MBA-Finance from Indiana University.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
Benjamin Shepherd, editor of Global Investment Strategist (http://www.globalinvestmentstrategist.com), focuses on time-tested investment strategies and high growth emerging markets which have proven themselves in both bull and bear cycles. He and his team spend hours every month discussing the state of the global economy and the markets with many of the best known and well-respected money managers in the industry. They then distill that wisdom and their own analysis into actionable advice geared towards generating returns while preserving capital for equity investors. Mr. Shepherd is also editor of Benjamin Shepherd's Wall Street, formerly Louis Rukeyser's Wall Street, and associate editor of Personal Finance, one of the world’s most widely-read investment newsletters, contributing his knowledge of the fund industry and emerging markets to the newsletter’s ongoing commentary.
KLLJ is a private investor focusing on small cap stocks in biotechnology, emerging markets and renewable energy. I have been an active investor for 15 years and focus on picking stocks with tremendous upside. I enjoy sharing my thoughts in forums such as Seeking Alpha to help with my own due diligence process. I'm a critical thinker who appreciated constructive feedback to my investing ideas. I am not a short-term or momentum trader and like to think my strength is in picking good stocks with 10X potential returns. I don't believe in relying on Wall Street coverage of companies because of the inherent conflicts of interest (known or unknown.) We are in the market to make money and it is up to you, the individual retail investor to perform your own analysis for investment decisions if you want to win in the market. My analysis and viewpoints are not investment advice and you should always perform your own due diligence.